MDxHealth SA (NASDAQ:MDXH) Stock Has Average Price Target of $1.33 According to Brokerages

MDxHealth SA (NASDAQ:MDXH) has earned a consensus recommendation of “Hold” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $1.33.

Several research analysts recently commented on the company. Wall Street Zen upgraded MDxHealth to a “sell” rating in a research report on Saturday, August 15th. BTIG Research downgraded shares of MDxHealth from a “buy” rating to a “neutral” rating in a research note on Monday, October 19th. Craig Hallum cut shares of MDxHealth from a “buy” rating to a “hold” rating in a research report on Friday, October 16th. Lake Street Capital cut shares of MDxHealth from a “buy” rating to a “hold” rating and set a $0.50 price objective for the company. in a research report on Friday, October 16th. Finally, Weiss Ratings downgraded shares of MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th.

MDxHealth Stock Performance

Shares of MDxHealth stock opened at $0.16 on Thursday. MDxHealth has a 52-week low of $0.15 and a 52-week high of $4.83. The stock has a market capitalization of $7.74 million, a PE ratio of -0.22 and a beta of 1.81. The company has a 50-day simple moving average of $0.52 and a two-hundred day simple moving average of $1.49.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. The company had revenue of $27.21 million for the quarter, compared to analysts’ expectations of $26.14 million. As a group, equities research analysts forecast that MDxHealth will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of MDxHealth by 213.9% in the 1st quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in MDxHealth by 21.8% during the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock worth $701,000 after buying an additional 54,600 shares during the period. Perkins Capital Management Inc. boosted its stake in MDxHealth by 7.1% in the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after acquiring an additional 97,500 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of MDxHealth during the second quarter worth about $82,000.

About MDxHealth

MDxHealth SA (NASDAQ: MDXH) is a molecular diagnostics company focused on helping physicians make more informed decisions in cancer care. The company develops and commercializes genomic and epigenetic tests designed to support cancer detection, diagnosis, prognosis and treatment planning.

MDxHealth’s portfolio has primarily centered on prostate cancer. Its ConfirmMDx test analyzes prostate tissue to help identify patients who may have clinically significant cancer despite an initially negative biopsy, while SelectMDx is a urine-based test intended to help assess the likelihood of clinically significant prostate cancer and guide decisions about biopsy.